Additional data show that liraglutide reduces several markers of cardiovascular risk, such as body weight, A1C levels, Systolic BP, C-reactive protein, type 2 natriuretic peptide, and PAI-1 [108, 109]
"It doesn't have to be complicated," Codorniz says
There have now been many studies and analyses that suggest that the use of GLP-1 drugs goes beyond just weight loss and diabetes, with potential benefits ranging from helping mental illness and substance abuse to kidney disease, heart disease and even osteoarthritis, he added
The overall trend matters more than any single week. Results May Slow, Pause, or Change Over Time Weight-loss progress may not continue at the same rate every month
Zepbound (tirzepatide)